Research Article: BRAF/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country
Abstract:
Introduction: Most pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income-countries (LMICs) are limited.
No summary available.